Regeneration of fat cells from myofibroblasts during wound healing

See allHide authors and affiliations

Science  17 Feb 2017:
Vol. 355, Issue 6326, pp. 748-752
DOI: 10.1126/science.aai8792

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Enter the characters shown in the image.

Vertical Tabs

  • RE: The truth about issue raised in Science articles regarding fibroblasts, fat production, and wound healing.

    Review of a career's worth of ultrastructural diagnostic and research pathology data revealed findings that impact on recent Science publications (Insight: "Fibroblasts become fat to reduce scarring", p. 693: Research article: "Regeneration of fat cells from myofibroblasts during wound healing" p. 748. 17 February 2017). The "Myofibroblasts" considered to be unique cells, are actually activated fibroblasts and modified smooth muscle cells (mSMC) (1,2). Both cells are involved in physiologic wound healing and Dupuytren's contracture (AKA disease) (3). The mSMC is a pathognomonic cell in stenosing arteriopathies including arteriosclerosis, Kawasaki disease, restenosis, and renal arterial dysplasia (4). There has never been the necessary morphologic evidence to support the claim that the embryologic reversible epithelial-mesenchymal transition (EMT) program actually exists in the post-natal period, and now there is ultrastructural proof that it does not exist with normal and pathologic cells, including those in cancers and organ fibrosis (5). The fibrogenic cell in organ fibrosis is the activated interstitial fibroblast. The mesenchymal cell of EMT is a non-existent MF. Carcinoma invasion and metastasis do not require the transition of cancer/carcinoma cells into sarcoma cells/sarcomas. Finally, heterologous expression by normal and malignant fibroblasts and its mesenchymal stem cell produces lipoblasts, chondroblasts, oste...

    Show More
    Competing Interests: None declared.

Navigate This Article